News from flexion therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 08, 2014, 16:58 ET

Flexion Therapeutics Files Registration Statement for Proposed Initial Public Offering

 Flexion Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange...

Oct 30, 2013, 08:30 ET

Flexion Therapeutics Presents Robust Phase 2b Data for FX006 at 2013 American College of Rheumatology Annual Scientific Meeting

Flexion Therapeutics, Inc. announced today that new data from a Phase 2b dose-ranging clinical trial of the company's lead compound, FX006, were...

Oct 02, 2013, 09:00 ET
Jun 26, 2013, 08:00 ET

Flexion's FX006 Demonstrates Superior Pain Relief Compared to Standard-of-Care in Phase 2b Osteoarthritis Trial

 Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular (IA), sustained release steroid, demonstrated...

May 20, 2013, 08:21 ET

Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer

 Flexion Therapeutics, Inc. today announced the addition of Frederick W. Driscoll to its management team as chief financial officer. Mr....

Apr 18, 2013, 16:30 ET

Data Presented at OARSI's 2013 World Congress on Osteoarthritis Show Flexion's FX006 Has Prolonged Therapeutic Concentration in Knee Joint

Flexion Therapeutics, Inc. announced today the presentation of a poster titled "FX006 prolongs the residency of triamcinolone acetonide in the...

Jan 04, 2013, 08:00 ET

Flexion Therapeutics to Present at 31st Annual J.P. Morgan Healthcare Conference

 Flexion Therapeutics, Inc., a clinical-stage specialty pharmaceutical company developing innovative therapeutics for musculoskeletal...

Dec 17, 2012, 08:00 ET

Flexion's FX006 Achieves Prolonged Therapeutic Concentrations in Joints of Osteoarthritis Patients

 Flexion Therapeutics, Inc. today reported that FX006, its novel intra-articular, sustained release steroid, maintained therapeutic...

Dec 04, 2012, 00:01 ET

Flexion Therapeutics Secures $20 Million in Series B Financing

Flexion Therapeutics, Inc. today announced that the company has secured $20 million in a Series B financing round led by new investor, Novo...

Jun 19, 2012, 17:00 ET

Flexion Therapeutics Names Arthur Fratamico Chief Business Officer

 Flexion Therapeutics, Inc. today announced that Arthur J. Fratamico, R.Ph., has joined the company as its first chief business officer. He has...

May 30, 2012, 07:30 ET

Flexion's Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial

Flexion Therapeutics, Inc. today reported that its lead osteoarthritis drug candidate, FX005, demonstrated significant pain relief over placebo at...